Wen is a member of the Wellington Management Health Care Team, which manages nearly $60B in dedicated health care assets. Wen conducts fundamental research on public and private global biotechnology companies, and is the portfolio manager of Wellington's long-only and long/short dedicated biopharmaceutical strategies.

Prior to joining Wellington Management in 2015, Wen was a member of the global biotechnology team at Sanford C. Bernstein, and previously was a consultant to biotech and pharmaceutical companies while at Campbell Alliance, Navigant Consulting, and McKinsey & Company. Wen earned his DPhil (PhD) in medical oncology from Oxford University, where he was a Rhodes Scholar (2007), and BS in biology from Johns Hopkins University (2004). Additionally, he holds the Chartered Financial Analyst designation and is a member of the CFA Institute and the CFA Society Boston.